Panelists discuss how early relapse in standard-risk patients represents a failure of current risk assessment methods and may require advanced sequencing technologies to identify hidden high-risk features that traditional fluorescence in situ hybridization testing misses.
This segment examines the challenges of early relapse in patients initially presenting with standard-risk multiple myeloma disease and discusses the role of clonal evolution in this context. Early relapse often represents a failure in current risk assessment capabilities at diagnosis, highlighting limitations in traditional fluorescence in situ hybridization (FISH) technologies. The discussion advocates for transitioning to more comprehensive sequencing technologies that can provide detailed genetic information and potentially identify subtle high-risk features missed by conventional testing methods.
Functionally high-risk patients—those without high-risk genetics at diagnosis who relapse within 3 years of transplant—present particularly challenging clinical scenarios requiring departure from standard treatment algorithms. Specific examples include patients with IGL translocations presenting with hyperdiploid genetics that appear favorable but actually confer high-risk characteristics and relative insensitivity to immunomodulatory agents. These subtle genetic features can only be detected through advanced sequencing technologies rather than standard FISH testing.
The management of early-relapse patients extends beyond genetic considerations to include extramedullary disease and circulating plasma cells as important prognostic factors. Despite advances in achieving MRD-negative responses and improved progression-free survival, early relapse patients continue to surprise both patients and physicians. The panel expresses enthusiasm for immunotherapy approaches, including bispecific antibodies, trispecific antibodies, and CAR T-cell therapies, as these novel modalities may effectively target disease that differs from typical myeloma through alternative mechanisms of action.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Corticosteroid Premedication for Infliximab Remains Unnecessarily Common
July 8th 2025Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More